

### Electronic Submissions

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

### Written/Paper Submissions

Submit written/paper submissions as follows:

- **Mail/Hand delivery/Courier (for written/paper submissions):** Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in "Instructions."

**Instructions:** All submissions received must include the Docket No. FDA-2024-N-4085 for "Advancing Smoking Cessation: Food and Drug Administration and National Institutes of Health Priorities." Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as "Confidential Submissions," publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.

- **Confidential Submissions—**To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two

copies total. One copy will include the information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.

**Docket:** For access to the docket to read background documents or the electronic and written/paper comments received, go to <https://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.

**FOR FURTHER INFORMATION CONTACT:** Laura Chilaka, Center for Tobacco Products, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993, 877-287-1373, [TobaccoCessation@fda.hhs.gov](mailto:TobaccoCessation@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** On September 23, 2024, FDA published in the **Federal Register** a notice announcing a public meeting entitled "Advancing Smoking Cessation: Food and Drug Administration and National Institutes of Health Priorities." Jointly convened by FDA and the National Institutes of Health, this public meeting addressed the need for novel smoking cessation products to help individuals of all ages, including underserved and vulnerable populations, stop smoking.

Interested persons were originally given until November 21, 2024, to submit comments on the public meeting.

FDA has received requests for additional time in submitting comments. Due to the significant

interest in the topic and to allow interested parties time to review the meeting transcript and recording, FDA has reopened the comment period until December 20, 2024.

Dated: November 25, 2024.

**P. Ritu Nalubola,**

*Associate Commissioner for Policy.*

[FR Doc. 2024-28205 Filed 11-29-24; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Recharter for the National Advisory Council on Nurse Education and Practice

**AGENCY:** Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, HHS is hereby giving notice that the National Advisory Council on Nurse Education and Practice (NACNEP or Council) is rechartered.

**DATES:** The effective date of the recharter is November 30, 2024.

**FOR FURTHER INFORMATION CONTACT:** Justin Bala-Hampton, Bureau of Health Workforce, HRSA, 5600 Fishers Lane, Rockville, Maryland 20857; 301-443-2765 or [BHWNAACNEP@hrsa.gov](mailto:BHWNAACNEP@hrsa.gov).

**SUPPLEMENTARY INFORMATION:** NACNEP provides advice and recommendations to the Secretary of HHS and Congress on policy matters and the preparation of general regulations concerning activities under title VIII of the Public Health Service Act, including the range of issues relating to the nurse workforce, education, and practice improvement. NACNEP also prepares and submits an annual report to the Secretary of HHS and Congress describing its activities, including NACNEP's findings and recommendations concerning activities under title VIII, as required by the Public Health Service Act. The recharter of NACNEP was approved on October 31, 2024. The filing date for the NACNEP recharter is November 30, 2024. The recharter of NACNEP gives authorization for the Council to operate until November 30, 2026.

A copy of the NACNEP charter is available on the NACNEP website at <https://www.hrsa.gov/advisorycommittees/nursing/about.html>. A copy of the charter can also be obtained by accessing the FACA database that is

maintained by the Committee Management Secretariat under the General Services Administration. The website address for the FACA database is <https://www.facadatabase.gov/>.

**Maria G. Button,**

*Director, Executive Secretariat.*

[FR Doc. 2024-28087 Filed 11-29-24; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Meeting of the Advisory Committee on Infant and Maternal Mortality

**AGENCY:** Health Resources and Services Administration (HRSA), Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, this notice announces that the Advisory Committee on Infant and Maternal Mortality (ACIMM or Committee) has scheduled a public meeting. Information about ACIMM and the agenda for this meeting can be found on the ACIMM website at <https://www.hrsa.gov/advisory-committees/infant-mortality/index.html>.

**DATES:** January 7, 2025, from 12:00 p.m. to 5:00 p.m. Eastern Time and January 8, 2025, from 12:00 p.m. to 5:00 p.m. Eastern Time.

**ADDRESSES:** This meeting will be held by webinar. *The webinar link and log-in information will be available at the ACIMM website before the meeting:* <https://www.hrsa.gov/advisory-committees/infant-mortality/index.html>.

**FOR FURTHER INFORMATION CONTACT:**

Vanessa Lee, MPH, Designated Federal Official, Maternal and Child Health Bureau, HRSA, 5600 Fishers Lane, Rockville, Maryland, 20857; 301-443-0543; or [SACIM@hrsa.gov](mailto:SACIM@hrsa.gov).

**SUPPLEMENTARY INFORMATION:** ACIMM is authorized by section 222 of the Public Health Service Act (42 U.S.C. 217a), as amended. The Committee is governed by provisions of the Federal Advisory Committee Act (5 U.S.C. Chapter 10), as amended.

ACIMM advises the Secretary of Health and Human Services on department activities, partnerships, policies, and programs directed at reducing infant mortality, maternal mortality, and severe maternal morbidity and improving the health status of infants and women before, during, and after pregnancy. The

Committee provides advice on how to coordinate federal, state, local, tribal, and territorial governmental efforts designed to improve infant mortality; related adverse birth outcomes; and maternal health; as well as influence similar efforts in the private and voluntary sectors. The Committee provides guidance and recommendations on the policies, programs, and resources required to address the disparities and inequities in infant mortality; related adverse birth outcomes and maternal health outcomes, including maternal mortality and severe maternal morbidity. With its focus on underlying causes of the disparities and inequities seen in birth outcomes for women and infants, the Committee advises the Secretary of Health and Human Services on the health, social, economic, and environmental factors contributing to the inequities and proposes structural, policy, and/or systems level changes.

The agenda for the January 7-8, 2025, meeting is being finalized and may include the following topics: federal updates; Committee operations updates; discussion of draft recommendations for the Secretary on achieving optimal maternal health and overall birth outcomes for underserved populations, including Black/African-American families; and a vote on whether to send the draft recommendations forward. Agenda items are subject to change as priorities dictate. Refer to the ACIMM website listed above for any updated information concerning the meeting.

Members of the public will have the opportunity to provide written or oral comments. Public participants may submit written statements in advance of the scheduled meeting by emailing [SACIM@hrsa.gov](mailto:SACIM@hrsa.gov). Oral comments will be presented in the order they are requested and may be limited as time allows. Requests to submit a written statement or make oral comments to ACIMM should be sent to Vanessa Lee, Designated Federal Official, using the email address above, at least 3 business days prior to the meeting.

Individuals who plan to attend and need special assistance or another reasonable accommodation should notify Vanessa Lee at the contact information listed above at least 10 business days prior to the meeting.

**Maria G. Button,**

*Director, Executive Secretariat.*

[FR Doc. 2024-28155 Filed 11-29-24; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Meeting of the Advisory Committee on Minority Health

**AGENCY:** Office of Minority Health, Office of the Secretary, U.S. Department of Health and Human Services.

**ACTION:** Notice of meeting.

**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services (HHS) is hereby giving notice that the Advisory Committee on Minority Health (ACMH) will hold a meeting conducted as a webcast on December 16, 2024. This virtual meeting will be open to the public. Registration is required for the public to attend the meeting, provide comment, and/or distribute material(s) to ACMH members.

**DATES:** The virtual ACMH meeting will be held on December 16, 2024, from 2 p.m. to 3:30 p.m. eastern standard time (EST). If the Committee completes its work before 3:30 p.m. EST, the meeting will adjourn early.

**ADDRESSES:** The meeting will be held virtually and will be accessible by webcast. Instructions regarding webcast access and providing written public comments will be given after meeting registration occurs.

Any individual who wishes to participate in the virtual meeting should register using the Zoom registration link provided below by 5 p.m. EST on December 12, 2024. Instructions regarding participating in the call and providing written or verbal public comments will be provided after meeting registration occurs. Information about the meeting will be posted on the HHS Office of Minority Health (OMH) website: [www.minorityhealth.hhs.gov](http://www.minorityhealth.hhs.gov). Information about ACMH activities can be found on the OMH website under the heading *About OMH, Committees and Working Groups*.

**FOR FURTHER INFORMATION CONTACT:** Violet Woo, Designated Federal Officer, Advisory Committee on Minority Health, OMH, HHS, Tower Building, 1101 Wootton Parkway, Suite 100, Rockville, Maryland 20852. Phone: 240-453-6816; email: [OMH-ACMH@hhs.gov](mailto:OMH-ACMH@hhs.gov).

**SUPPLEMENTARY INFORMATION:** In accordance with Public Law 105-392, the ACMH was established to provide advice to the Deputy Assistant Secretary for Minority Health on the development of goals and program activities related to OMH's duties.

The topics to be discussed during the virtual meeting include finalizing: (1)